Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Alfuzosin Versus Placebo in Acute Urinary Retention (ALF-RIK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00453908
Recruitment Status : Terminated (The study was early terminated due to slow and difficult recruitment)
First Posted : March 29, 2007
Last Update Posted : August 20, 2007
Information provided by:

Brief Summary:

The primary objective of the study is to investigate if 14 days of treatment with Alfuzosin compared to placebo, will increase the number of patients with satisfying spontaneous voiding after acute urinary retention treated with Clean Self-Catheterization.

Furthermore is investigated the safety of the medical treatment and self-catheterization.

Condition or disease Intervention/treatment Phase
Urinary Retention Drug: Alfuzosin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Does Alfuzosin OD vs. Placebo in Male Patients Facilitate Spontaneous Voiding During Clean Intermittent Self-Catheterization Following Acute Urinary Retention?
Study Start Date : May 2004

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Number of patients with satisfying spontaneous voiding after 14 days measured by bladder scan at day 14.

Secondary Outcome Measures :
  1. Number of days until termination of self catheterization
  2. Number of patients with urinary infection requiring treatment
  3. Pressure of voiding, volume of voiding, residual urine after voiding, measured by urine culture and bladder scan at day 14.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men with acute urinary retention and catheterized
  • Benign hypertrophia of prostate
  • Patient is diagnosed in Emergency room or at a acute hospitalization

Exclusion Criteria:

  • Known prostate cancer
  • Prior urinary retention within 30 days
  • Urinary retention occurring in relation to surgery
  • Blood in urine
  • Difficult or impossible catheterization
  • Fever > 38 degree Celsius
  • Decreased kidney function
  • Permanent catheter > 14 days
  • Treatment with alfa 1 blocker within 30 days
  • Meeting contraindications to treatment with Alfuzosin
  • Treatment with other drugs for urinary problems

The above information is not intended to contain all considerations relevant to a patients potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00453908

Layout table for location information
Hoersholm, Denmark
Sponsors and Collaborators
Layout table for investigator information
Study Director: Henning Andersen, MD Sanofi
Layout table for additonal information Identifier: NCT00453908    
Other Study ID Numbers: L_9397
First Posted: March 29, 2007    Key Record Dates
Last Update Posted: August 20, 2007
Last Verified: August 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Retention
Urination Disorders
Urologic Diseases
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents